Multiple Myeloma Coverage from Every Angle

Saad Z. Usmani, MBA, MD: Expert Perspective on the Use of Ciltacabtagene Autoleucel in Multiple Myeloma

Posted: Tuesday, September 28, 2021

Saad Z. Usmani, MBA, MD, of the Levine Cancer Institute, discusses new findings in patients with relapsed or refractory multiple myeloma who were given a single infusion of ciltacabtagene autoleucel and experienced responses, and what it could mean clinically going forward, especially for those receiving later lines of therapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.